Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 59 articles:
HTML format



Single Articles


    March 2023
  1. ZHOU Q, Ou Y, Dai X, Chen X, et al
    Correction to: Prevalence of tumour-infiltrating CD103(+) cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome.
    Br J Cancer. 2023 Mar 20. doi: 10.1038/s41416-023-02211.
    PubMed    


    February 2023
  2. ZHOU Q, Ou Y, Dai X, Chen X, et al
    Prevalence of tumour-infiltrating CD103(+) cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome.
    Br J Cancer. 2023 Feb 9. doi: 10.1038/s41416-023-02183.
    PubMed     Abstract available


    January 2023
  3. TAO W, Luo ZH, He YD, Wang BY, et al
    Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer.
    Br J Cancer. 2023 Jan 26. doi: 10.1038/s41416-023-02147.
    PubMed     Abstract available


  4. LI J, Liu N, Zhou H, Xian P, et al
    Immunoproteasome inhibition prevents progression of castration-resistant prostate cancer.
    Br J Cancer. 2023 Jan 21. doi: 10.1038/s41416-022-02129.
    PubMed     Abstract available


  5. BAO J, Hou Y, Qin L, Zhi R, et al
    High-throughput precision MRI assessment with integrated stack-ensemble deep learning can enhance the preoperative prediction of prostate cancer Gleason grade.
    Br J Cancer. 2023 Jan 17. doi: 10.1038/s41416-022-02134.
    PubMed     Abstract available


  6. LIN J, Nousome D, Jiang J, Chesnut GT, et al
    Five-year survival of patients with late-stage prostate cancer: comparison of the Military Health System and the U.S. general population.
    Br J Cancer. 2023 Jan 6. doi: 10.1038/s41416-022-02136.
    PubMed     Abstract available


  7. YU R, Jiang KW, Bao J, Hou Y, et al
    PI-RADS(AI): introducing a new human-in-the-loop AI model for prostate cancer diagnosis based on MRI.
    Br J Cancer. 2023 Jan 4. doi: 10.1038/s41416-022-02137.
    PubMed     Abstract available


    December 2022
  8. CARDOSO M, Maia S, Brandao A, Sahasrabudhe R, et al
    Exome sequencing of affected duos and trios uncovers PRUNE2 as a novel prostate cancer predisposition gene.
    Br J Cancer. 2022 Dec 23. doi: 10.1038/s41416-022-02125.
    PubMed     Abstract available


  9. BLANC C, Moktefi A, Jolly A, de la Grange P, et al
    The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer.
    Br J Cancer. 2022 Dec 22. doi: 10.1038/s41416-022-02114.
    PubMed     Abstract available


  10. GREEN HD, Merriel SWD, Oram RA, Ruth KS, et al
    Response to: Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis (BJC-LT3342090).
    Br J Cancer. 2022 Dec 19. doi: 10.1038/s41416-022-02081.
    PubMed    


  11. LIN E, Garmo H, Hagstrom E, Van Hemelrijck M, et al
    Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden.
    Br J Cancer. 2022 Dec 15. doi: 10.1038/s41416-022-02091.
    PubMed     Abstract available


  12. HARTLEY A, Ahmad I
    The role of PPARgamma in prostate cancer development and progression.
    Br J Cancer. 2022 Dec 12. doi: 10.1038/s41416-022-02096.
    PubMed     Abstract available


  13. PEDERZOLI F, Raffo M, Pakula H, Ravera F, et al
    "Stromal cells in prostate cancer pathobiology: friends or foes?".
    Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02085.
    PubMed     Abstract available


    November 2022
  14. HORTON RH, Dunlop MG, Houlston RS, Lucassen A, et al
    Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis.
    Br J Cancer. 2022 Nov 28. doi: 10.1038/s41416-022-02080.
    PubMed    


  15. ROULEAU M, Nguyen Van Long F, Turcotte V, Caron P, et al
    Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer.
    Br J Cancer. 2022 Nov 8. pii: 10.1038/s41416-022-02040.
    PubMed     Abstract available


  16. EGGER S, Smith DP, Patel MI, Kimlin MG, et al
    Cutaneous melanoma, prostate-specific antigen testing and the subsequent risk of prostate cancer diagnosis: a prospective analysis of the 45 and Up Study.
    Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02027.
    PubMed     Abstract available


    October 2022
  17. LAN T, Park Y, Colditz GA, Liu J, et al
    Adolescent dietary patterns in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study.
    Br J Cancer. 2022 Oct 31. pii: 10.1038/s41416-022-02035.
    PubMed     Abstract available


  18. BUTLER EN, Zhou CK, Curry M, McMenamin U, et al
    Testosterone therapy and cancer risks among men in the SEER-Medicare linked database.
    Br J Cancer. 2022 Oct 28. pii: 10.1038/s41416-022-02019.
    PubMed     Abstract available


  19. RODRIGUEZ-VIDA A, Maroto P, Font A, Martin C, et al
    Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
    Br J Cancer. 2022 Oct 26. pii: 10.1038/s41416-022-01991.
    PubMed     Abstract available


  20. CROWLEY F, Mihalopoulos M, Gaglani S, Tewari AK, et al
    Prostate cancer in transgender women: considerations for screening, diagnosis and management.
    Br J Cancer. 2022 Oct 19. pii: 10.1038/s41416-022-01989.
    PubMed     Abstract available


  21. GLUD EN, Rasmussen M, Zhang Y, Mandrup OA, et al
    Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 x anti-PSMA bispecific design.
    Br J Cancer. 2022 Oct 15. pii: 10.1038/s41416-022-01994.
    PubMed     Abstract available


    August 2022
  22. GRAFF RE, Langlais CS, Van Blarigan EL, Pernar CH, et al
    Post-diagnostic health behaviour scores in relation to fatal prostate cancer.
    Br J Cancer. 2022 Aug 26. pii: 10.1038/s41416-022-01948.
    PubMed     Abstract available


  23. KIMURA H, Mizuno K, Shiota M, Narita S, et al
    Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.
    Br J Cancer. 2022 Aug 19. pii: 10.1038/s41416-022-01915.
    PubMed     Abstract available


  24. GREEN HD, Merriel SWD, Oram RA, Ruth KS, et al
    Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK Biobank.
    Br J Cancer. 2022 Aug 18. pii: 10.1038/s41416-022-01918.
    PubMed     Abstract available


    July 2022
  25. SACHDEVA A, Hart CA, Kim K, Tawadros T, et al
    Non-canonical EphA2 activation underpins PTEN-mediated metastatic migration and poor clinical outcome in prostate cancer.
    Br J Cancer. 2022 Jul 22. pii: 10.1038/s41416-022-01914.
    PubMed     Abstract available


    June 2022
  26. TRUJILLO B, Wu A, Wetterskog D, Attard G, et al
    Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01881.
    PubMed     Abstract available


    May 2022
  27. NAIR-SHALLIKER V, Bang A, Egger S, Yu XQ, et al
    Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study.
    Br J Cancer. 2022 May 24. pii: 10.1038/s41416-022-01827.
    PubMed     Abstract available


  28. SALMINEN JK, Mehtola A, Talala K, Taari K, et al
    Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer.
    Br J Cancer. 2022 May 3. pii: 10.1038/s41416-022-01817.
    PubMed     Abstract available


    April 2022
  29. OWARI T, Tanaka N, Nakai Y, Miyake M, et al
    5-Aminolevulinic acid overcomes hypoxia-induced radiation resistance by enhancing mitochondrial reactive oxygen species production in prostate cancer cells.
    Br J Cancer. 2022 Apr 1. pii: 10.1038/s41416-022-01789.
    PubMed     Abstract available


  30. RASMUSSEN M, Fredsoe J, Tin AL, Vickers AJ, et al
    Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence.
    Br J Cancer. 2022;126:1004-1009.
    PubMed     Abstract available


    March 2022
  31. SALBERG UB, Skingen VE, Fjeldbo CS, Hompland T, et al
    A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients.
    Br J Cancer. 2022 Mar 24. pii: 10.1038/s41416-022-01782.
    PubMed     Abstract available


    February 2022
  32. SLOOTBEEK PHJ, Kloots ISH, Smits M, van Oort IM, et al
    Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
    Br J Cancer. 2022 Feb 24. pii: 10.1038/s41416-022-01765.
    PubMed    


    January 2022
  33. RANA S, Valbuena GN, Curry E, Bevan CL, et al
    MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data.
    Br J Cancer. 2022 Jan 12. pii: 10.1038/s41416-021-01677.
    PubMed     Abstract available


    December 2021
  34. NYBERG T, Tischkowitz M, Antoniou AC
    BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.
    Br J Cancer. 2021 Dec 28. pii: 10.1038/s41416-021-01675.
    PubMed     Abstract available


  35. MCHUGH J, Saunders EJ, Dadaev T, McGrowder E, et al
    Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.
    Br J Cancer. 2021 Dec 18. pii: 10.1038/s41416-021-01669.
    PubMed     Abstract available


  36. SLOOTBEEK PHJ, Kloots ISH, Smits M, van Oort IM, et al
    Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01663.
    PubMed     Abstract available


    November 2021
  37. SRIVASTAVA SK, Khan MA, Anand S, Zubair H, et al
    MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer.
    Br J Cancer. 2021 Nov 26. pii: 10.1038/s41416-021-01641.
    PubMed     Abstract available


  38. WEN YC, Liu CL, Yeh HL, Chen WH, et al
    PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer.
    Br J Cancer. 2021 Nov 24. pii: 10.1038/s41416-021-01631.
    PubMed     Abstract available


  39. RAMIREZ-GARRASTACHO M, Berge V, Line A, Llorente A, et al
    Potential of miRNAs in urinary extracellular vesicles for management of active surveillance in prostate cancer patients.
    Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01598.
    PubMed     Abstract available


  40. RAMIREZ-GARRASTACHO M, Bajo-Santos C, Line A, Martens-Uzunova ES, et al
    Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research.
    Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01610.
    PubMed     Abstract available


  41. HATANO K, Yoneyama T, Hatakeyama S, Tomiyama E, et al
    Simultaneous analysis of serum alpha2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer.
    Br J Cancer. 2021 Nov 20. pii: 10.1038/s41416-021-01637.
    PubMed     Abstract available


  42. NA R, Wei J, Sample CJ, Gielzak M, et al
    The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients.
    Br J Cancer. 2021 Nov 19. pii: 10.1038/s41416-021-01622.
    PubMed     Abstract available


    September 2021
  43. YU H, Xie M, Meng Z, Lo CY, et al
    Endolysosomal ion channel MCOLN2 (Mucolipin-2) promotes prostate cancer progression via IL-1beta/NF-kappaB pathway.
    Br J Cancer. 2021 Sep 21. pii: 10.1038/s41416-021-01537.
    PubMed     Abstract available


  44. KAKOURATOS C, Kalamida D, Lamprou I, Xanthopoulou E, et al
    Apalutamide radio-sensitisation of prostate cancer.
    Br J Cancer. 2021 Sep 1. pii: 10.1038/s41416-021-01528.
    PubMed     Abstract available


  45. LIU Z, Thong MSY, Doege D, Koch-Gallenkamp L, et al
    Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany.
    Br J Cancer. 2021;125:877-883.
    PubMed     Abstract available


    July 2021
  46. DE GIORGI U, Sansovini M, Severi S, Nicolini S, et al
    Circulating androgen receptor gene amplification and resistance to (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial.
    Br J Cancer. 2021 Jul 31. pii: 10.1038/s41416-021-01508.
    PubMed     Abstract available


  47. ZHAO Z, Zhao S
    Reply to Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition".
    Br J Cancer. 2021 Jul 20. pii: 10.1038/s41416-021-01493.
    PubMed    


  48. AHMAD F, Cherukuri MK, Choyke PL
    Metabolic reprogramming in prostate cancer.
    Br J Cancer. 2021 Jul 14. pii: 10.1038/s41416-021-01435.
    PubMed     Abstract available


  49. SUI Y, Hu W, Zhang W, Li D, et al
    Insights into homeobox B9: a propeller for metastasis in dormant prostate cancer progenitor cells.
    Br J Cancer. 2021 Jul 10. pii: 10.1038/s41416-021-01482.
    PubMed     Abstract available


    June 2021
  50. SJOBERG HT, Philippou Y, Magnussen AL, Tullis IDC, et al
    Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
    Br J Cancer. 2021 Jun 21. pii: 10.1038/s41416-021-01450.
    PubMed     Abstract available


  51. LAN T, Park Y, Colditz GA, Liu J, et al
    Adolescent animal product intake in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study.
    Br J Cancer. 2021 Jun 16. pii: 10.1038/s41416-021-01463.
    PubMed     Abstract available


  52. CHEN F, Han Y, Kang Y
    Bone marrow niches in the regulation of bone metastasis.
    Br J Cancer. 2021;124:1912-1920.
    PubMed     Abstract available


    May 2021
  53. CRISTOBAL I, Santos A, Rubio J, Rojo F, et al
    Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition".
    Br J Cancer. 2021 May 19. pii: 10.1038/s41416-021-01433.
    PubMed    


  54. WOKOLORCZYK D, Kluzniak W, Stempa K, Rusak B, et al
    PALB2 mutations and prostate cancer risk and survival.
    Br J Cancer. 2021 May 18. pii: 10.1038/s41416-021-01410.
    PubMed     Abstract available


  55. FILON M, Gawdzik J, Truong A, Allen G, et al
    Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
    Br J Cancer. 2021 May 11. pii: 10.1038/s41416-021-01398.
    PubMed     Abstract available


  56. AMADOU A, Freisling H, Jenab M, Tsilidis KK, et al
    Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
    Br J Cancer. 2021;124:1882-1890.
    PubMed     Abstract available


    April 2021
  57. EMOND JP, Lacombe L, Caron P, Turcotte V, et al
    Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression.
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01376.
    PubMed     Abstract available


    February 2021
  58. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available


    December 2020
  59. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: